Regeneron(US:REGN) Prnewswire·2025-02-27 15:06Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Regeneron Pharmaceuticals, Inc. related to alleged violations of federal securities laws, particularly concerning misleading statements and undisclosed financial practices that may have inflated the reported sales of its drug Eylea [2][4][5]. Group 1: Allegations Against Regeneron - The complaint alleges that Regeneron made false and misleading statements regarding credit card fee payments to distributors, which were not disclosed as price concessions, leading to inflated sales figures for Eylea [4]. - It is claimed that Regeneron's actions provided a competitive advantage by subsidizing treatment costs, which misled investors about the company's true financial health [5]. - The U.S. Department of Justice filed a complaint against Regeneron under the False Claims Act, alleging that the company failed to report millions in discounts, resulting in inflated Average Selling Prices (ASP) for Eylea [5]. Group 2: Financial Impact and Stock Performance - Following the DOJ announcement, Regeneron's stock price fell by $31.50, or 3.36%, closing at $904.70 on April 12, 2024, with unusually heavy trading volume [6]. - On October 31, 2024, Regeneron reported third-quarter 2024 financial results, revealing only a 3% increase in U.S. net sales for Eylea compared to the previous year, with sales of Eylea HD at $392 million, missing consensus estimates [7]. - The stock price dropped by $84.59, or 9.2%, to close at $838.20 per share on the same day, indicating a significant market reaction to the disappointing sales figures [7]. Group 3: Legal Proceedings and Investor Actions - Investors who suffered losses exceeding $100,000 in Regeneron between November 2, 2023, and October 30, 2024, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1]. - There is a March 10, 2025, deadline for investors to seek the role of lead plaintiff in the federal securities class action against Regeneron [2]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Regeneron's conduct [9].